N-Nitroso-N-Methyl-4-Aminobutyric Acid (NMBA)

N-nitroso-N-methyl-4-aminobutyric acid (NMBA) is a type of nitrosamine. It is a tobacco-derived nitrosamino acid that is a known animal and potential human carcinogen. This compound has recently been identified as a contaminant in some blood pressure medications.

N-nitroso-N-methyl-4-aminobutyric acid (NMBA) is a low melting solid compound that has been identified as a potentially carcinogenic component of both tobacco and tobacco smoke. This compound is also one of a number of nitrosamine impurities that have been found to be present in some medications used to treat high blood pressure. This compound is for research use only and is not suitable for diagnostic, therapeutic, prophylactic or in vivo use.

N-nitroso-N-methyl-4-aminobutyric acid (NMBA) can only be stored for short periods at room temperature. Long-term storage at minus 20 degrees is recommended. For maximum recovery of the product, the bottle must be centrifuged before removing the cap.

This N-nitrosamino acid has been isolated and identified in various types of tobacco, including snuff, chewing and pipe tobacco, cigars, and cigarettes. The presence of N-nitrosamino acids is highly correlated with tobacco-specific N-nitrosamine levels, which are known to be carcinogenic in a wide variety of animal species.

Nitrosamines are undesirable chemical compounds, especially in the pharmaceutical, cosmetic and food industries. Nitrosamines naturally undergo nitrosation reactions under acidic pH and this has made nitrosamines compounds to be avoided. In fact, the carcinogenic properties of nitrosamines have been known for a long time. For example, N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA) and N-nitroso-N-methyl-4-aminobutyric acid (NMBA) have been identified as potentially carcinogenic compounds for humans according to the International Agency for Research on Cancer classification.

The American Food and Drug Administration (FDA) and other international organizations bring up the place of nitrosamines in the pharmaceutical, cosmetic and food industries from time to time.

Today, all commercially available pharmaceutical products and drug active ingredients are subjected to risk assessment for nitrosamines using analytical methods. N-nitroso-N-methyl-4-aminobutyric acid is among the 7 main N-nitrosamines used in risk assessment by the European Medicines Agency.

Our organization also provides N-nitroso-N-methyl-4-aminobutyric acid (NMBA) testing services with its trained and expert staff and advanced technological equipment, among the numerous test, measurement, analysis and evaluation studies it provides for businesses in various sectors.